MAPK3 and familial pancreatic carcinoma: As shown in Figure 3C, a decrease in cyclin D1 expression was observed in the AsPC1 cells treated with AKT and ERK1/2 inhibitors, suggesting the involvement of these pathways in the up-regulation of cyclin D1 in pancreatic cancer cells.